Saturday, April 16, 2016 4:36:00 PM
There were 10 RECIST complete or partial responses (CR/PR) out of 37 (15 BRCA m) evaluable pts, including gBRCA m breast (n=4), platinum-resistant gBRCA m ovarian (n=2), BRCA wildtype (WT) triple negative breast (n=1), BRCA WT ovarian (n=2) and BRCA unknown prostate (n=1) cancer pts.
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=946fbd6f-3560-4ea2-aed6-7788155ea81b&cKey=fbf921a7-552a-44ee-aa04-a345ece10ad8&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM